Fazackerley E J, Randall N P, Pleuvry B J, Bradbrook I, Mawer G E
Br J Clin Pharmacol. 1987 Feb;23(2):183-7. doi: 10.1111/j.1365-2125.1987.tb03027.x.
A volunteer study was undertaken to assess the respiratory effects of ethyl loflazepate, a new benzodiazepine, and to correlate these with plasma concentrations of the active metabolites. Twelve volunteers were given placebo, 2 mg ethyl loflazepate, and 6 mg ethyl loflazepate on separate occasions. Respiration and plasma metabolite levels were assessed hourly for 8 h and at 24 h. The 6 mg ethyl loflazepate treatment produced a significant decrease (P less than 0.02) in the ventilatory response to carbon dioxide at 5 h. However this did not equate with a peak in plasma metabolite concentrations which were maintained at a plateau level from 4 to 24 h.
开展了一项志愿者研究，以评估新型苯二氮䓬类药物氯氟卓乙酯对呼吸的影响，并将这些影响与活性代谢物的血浆浓度进行关联。12名志愿者在不同时间分别服用了安慰剂、2毫克氯氟卓乙酯和6毫克氯氟卓乙酯。每小时评估一次呼吸和血浆代谢物水平，持续8小时，并在24小时时进行评估。6毫克氯氟卓乙酯治疗在5小时时使对二氧化碳的通气反应显著降低（P小于0.02）。然而，这与血浆代谢物浓度的峰值并不对应，血浆代谢物浓度在4至24小时维持在平台水平。
